Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Catalyst Bio (CBIO)

Catalyst Bio (CBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,491
  • Shares Outstanding, K 11,980
  • Annual Sales, $ 10 K
  • Annual Income, $ -30,060 K
  • 60-Month Beta 2.38
  • Price/Sales 15,194.63
  • Price/Cash Flow N/A
  • Price/Book 0.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -1.20
  • Number of Estimates 1
  • High Estimate -1.20
  • Low Estimate -1.20
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -122.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.92 +7.95%
on 06/07/19
8.45 -11.60%
on 05/29/19
-0.43 (-5.44%)
since 05/24/19
3-Month
6.92 +7.95%
on 06/07/19
10.84 -31.09%
on 04/05/19
-0.93 (-11.07%)
since 03/26/19
52-Week
6.20 +20.48%
on 12/24/18
14.37 -48.02%
on 07/16/18
-4.13 (-35.60%)
since 06/26/18

Most Recent Stories

More News
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update

Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019

CBIO : 7.47 (-1.84%)
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration

A single intravitreal injection of 125 μg CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement factor 3 (C3) in non-human primates (NHP), supporting dosing...

CBIO : 7.47 (-1.84%)
New Research: Key Drivers of Growth for CBRE Group, Brookfield Asset Management, Zebra Technologies, Trex, Catalyst Biosciences, and Albireo Pharma -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CBRE Group, Inc. (NYSE:CBRE),...

TREX : 67.10 (-1.71%)
ALBO : 31.21 (+0.35%)
CBIO : 7.47 (-1.84%)
CBRE : 49.74 (-0.60%)
BAM : 47.52 (-0.31%)
ZBRA : 203.40 (+2.97%)
Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference

Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare...

CBIO : 7.47 (-1.84%)
Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B

Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX)...

CBIO : 7.47 (-1.84%)
Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)

Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment...

CBIO : 7.47 (-1.84%)
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update

Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with >90% reduction in bleeding

CBIO : 7.47 (-1.84%)
New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare Investors,...

CIDM : 1.38 (unch)
OHI : 36.37 (-1.81%)
ALGT : 137.40 (+2.15%)
ESE : 77.59 (+0.78%)
CBIO : 7.47 (-1.84%)
CSII : 41.61 (-0.07%)
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress

Results from the study demonstrate that subcutaneous MarzAA (FVIIa) significantly reduces both annualized bleed rate and the percentage of days with bleeding

CBIO : 7.47 (-1.84%)
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B

Results show a four-fold reduction in bleeding time for CB 2679d-GT and a three-fold improvement in clotting activity when compared with an AAV-encoding Padua vector

CBIO : 7.47 (-1.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CBIO with:

Business Summary

Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic...

See More

Key Turning Points

2nd Resistance Point 7.84
1st Resistance Point 7.66
Last Price 7.47
1st Support Level 7.33
2nd Support Level 7.18

See More

52-Week High 14.37
Fibonacci 61.8% 11.25
Fibonacci 50% 10.28
Fibonacci 38.2% 9.32
Last Price 7.47
52-Week Low 6.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar